Recently, a CTGF/MSLN tumor vaccine targeting MSLN-expressing malignant mesothelioma generated anti-tumor effects by decreasing tumor volumes and prolonging survival (Chen et al., 2018a). This evidence concerns the gene CCN2 and neoplasm.